Table 5.
Cox's multivariate analysis of factors contributing to survival of the 32 patients who underwent GTC treatment
| Characteristics | OS | PFS | ||
|---|---|---|---|---|
| P | HR (95.0% CI) | P | HR (95.0% CI) | |
| CEA concentration | – | – | 0.092 | 1.000 (0.996–1.000) |
| Lymph node metastasis | – | – | 0.775 | 1.224 (0.308–4.850) |
| Size of liver metastasis | 0.037* | 1.524 (1.108–2.707) | – | – |
| Extent of liver metastases | 0.001† | 3.182 (1.645–6.127) | 0.003* | 2.331 (1.324–4.092) |
| Radiofrequency ablation | 0.086 | 0.148 (0.018–1.304) | 0.146 | 0.169 (0.016–1.852) |
–: Not applicable; CEA: Carcinoembryonic antigen; CI: Confidence interval; HR: Hazard ratio; GTC: Gastrectomy, TACE, Chemotherapy; PFS: Progression-free survival; OS: Overall survival. *P<0.05, †P<0.01.